Why the study?
Does androgen deprivation therapy with gonadotropin-releasing hormone agonists increase the risk of cardiovascular complications?
Does androgen deprivation therapy with gonadotropin-releasing hormone agonists increase the risk of cardiovascular complications?
Answers are grounded in this paper and cite their sources.
This review highlights the potential mechanisms of cardiovascular toxicity associated with gonadotropin-releasing hormone agonists used in androgen deprivation therapy, emphasizing the need for caution in patients with preexisting cardiovascular disease.
Cardiovascular complications associated with the use of antiandrogens have already been known for some time. Based on the results of the latest meta-analyses and clinical studies published in the last few years, the attention of the scientific community is focused on the deleterious cardiovascular effects of gonadotropine-releasing hormon agonists in context of the androgen deprivating therapy. The cardiac toxicity is a problem especially in patients with preexisting cardiovascular comorbidities. Increased arterial wall thickening along with endothelial dysfunction has been observed in patients with descreased androgens levels in the peripheral blood. The treatment with gonadotropine-releasing hormon agonists may disrupt the intracellular concentration of calcium ions and the contractile process and potentially result in pathological remodelling of heart. Here, we give several possible mechanisms of action of gonadotropine-releasing hormon agonists on the cardiovascular system that may be a potential explanation of the clinical observations (Ref. 44).
No takes yet. Share an insight, caveat, or question.
Poljak et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: